IL6 and B-cell non-Hodgkin lymphoma: Initial experiments with copanlisib point to IL6 signaling as a main player in copanlisib resistance; levels of IL6 and phosphorylation of STAT5, Akt, p70S6K, and MAPK were increased in copanlisib-resistant B cell lymphoma cell lines and the resistance was reversible by JAK inhibitor (210).